MINNEAPOLIS, July 26, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the first quarter of fiscal 2013 ended June 30, 2012.
Global sales grew 20% to $5.6 million for the first quarter of fiscal 2013, compared with $4.7 million in the fiscal first quarter a year ago. Sales in the U.S. increased 40%, driven by a 64% increase in sales of the Urgent® PC Neuromodulation System. U.S. sales of Macroplastique were up 16% from the prior year.
Sales and other key metrics related to Urgent PC in the U.S. continued to demonstrate sequential quarterly progress in the fiscal first quarter of 2013. Sales in the first quarter totaled $2.5 million, 9% over $2.3 million in sales in the fiscal fourth quarter of 2012. The number of active customers of Urgent PC in the U.S increased sequentially to 577 in the first quarter compared with 538 in the fourth quarter of fiscal 2012. The Company sold 3,283 lead set boxes in the fiscal first quarter compared with 3,023 in the fiscal fourth quarter of 2012. Utilization in the fiscal first quarter increased to 5.7 lead set boxes per active customer compared with 5.6 in the fourth quarter.
"These first quarter results are a positive start to our new fiscal year, demonstrating solid traction on all of the key metrics for our U.S. Urgent PC operation," said David Kaysen, President and CEO of Uroplasty. "Execution of our strategy to bring on new physician customers and expand utilization within our existing accounts is going well. Since the administrative process for submitting Medicare claims in Florida was streamlined last quarter, we have seen growth in customers and sales in that region. We are aggressively pursuing our opportunities in the Mid-Atlantic region following the decision by Novitas Solutions (formerly Highmark Medicare Services) to provide coverage of percutaneous tibial nerve stimulation (PTNS) effective April 9th. With Novitas, PTNS treatments are covered by 11 of the 13 regional Medicare carriers."
"We also continue to expand our presence with private insurers. Last week we announced that EmblemHealth, one of the largest private insurance payers in the northeastern U.S., will offer reimbursement for PTNS treatments. EmblemHealth covers approximately 2.8 million lives in New York and New Jersey and we believe this represents a very promising market for Urgent PC. We are currently working to maximize these new opportunities and expect continued growth of Urgent PC in fiscal 2013," continued Mr. Kaysen.
First Quarter Fiscal 2013 ResultsUrgent PC sales in the U.S. were $2.5 million in the fiscal first quarter ended June 30, 2012, compared with $1.5 million in the same quarter last year, an increase of 64%. Macroplastique sales in the U.S. totaled $1.5 million in the recent first quarter compared to $1.3 million in the same quarter last year.
Net sales to customers outside of the U.S. for the fiscal first quarter totaled $1.5 million, a decrease of 14% from $1.8 million in the prior fiscal year's first quarter. Excluding the impact of fluctuations in foreign currency exchange rates, total sales outside the U.S. were down 6%. Urgent PC sales of $556,000 increased 27% from $437,000 in the prior fiscal year's first quarter. Excluding the impact of fluctuations in foreign currency exchange rates, Urgent PC sales increased 38%.
The Company reported an operating loss of $1.0 million in the fiscal first quarter, compared with a $1.3 million operating loss in the same quarter last year. Excluding non-cash charges for share-based compensation and depreciation and amortization expense, the non-GAAP operating loss was $561,000 in the first quarter of fiscal 2013, compared with a $934,000 non-GAAP operating loss in the first quarter a year ago. The decrease was primarily attributable to the increase in sales, which more than offset the increase in R&D, G&A and selling and marketing expenses.
Cash, cash equivalents and cash investments totaled $15.5 million at June 30, 2012 compared with $16.3 million at March 31, 2012. The Company used $0.7 million of cash for operating activities during the first fiscal quarter of 2013.
"Looking ahead, we are excited about several potential new developments that Uroplasty is pursuing. Our plans for a pilot study in the U.S.to evaluate the efficacy of Urgent PC in the treatment of bowel incontinence are moving forward. We have confirmed two sites and are working on the protocol to begin the study late this summer or early fall. We are also making progress on our efforts to secure a CE Mark in Europe for an implantable tibial nerve stimulator for the treatment of over active bladder. During fiscal 2013 we anticipate steady sales from Macroplastique and continued growth of Urgent PC, which will position us well for future opportunities," Mr. Kaysen concluded.
Conference CallUroplasty will host an audio conference call today at 3:30 pm Central, 4:30 pm Eastern, to review the financial results for the fiscal first quarter of 2013. David Kaysen, President and Chief Executive Officer, and Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will host the call. Individuals wishing to participate in the conference call should dial 877-941-8631. An audio replay will be available for 30 days following the call at 800-406-7325 (domestic) and 303-590-3030 (international), with the passcode 4550883#.
About Uroplasty, Inc. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
Forward-Looking InformationThis press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. In particular, we cannot be certain that we will ever achieve sustained profitability, that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment or that existing carriers and payers will not change their coverage decisions, that the rate of adoption of our products by new customers will continue, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.For Further Information: Uroplasty, Inc.
EVC Group David Kaysen, President and CEO, or
Jenifer Kirtland/Jamar Ismail (Investors) Medi Jiwani, Vice President, CFO, and
Chris Gale (Media) 952.426.6140
646.201.5431 UROPLASTY, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)Three Months EndedJune 30,20122011Net sales
$5,577,123$4,653,123Cost of goods sold
4,821,5363,943,557Operating expensesGeneral and administrative
1,091,8461,021,858Research and development
563,041455,760Selling and marketing
(1,013,795)(1,340,518)Other income (expense)Interest income
12,57817,834Foreign currency exchange (loss) gain
(9,671)5,3082,90723,142Loss before income taxes
(1,010,888)(1,317,376)Income tax expense
$(1,019,355)$(1,331,307)Basic and diluted loss per common share
$(0.05)$(0.06)Weighted average common shares outstanding:Basic and diluted
UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)June 30, 2012March 31, 2012AssetsCurrent assets:Cash and cash equivalents & short-term investments
$12,790,041$11,854,127Accounts receivable, net
468,052363,639Total current assets
16,707,84715,620,942Property, plant, and equipment, net
1,135,2751,171,979Intangible assets, net
2,685,6604,429,140Deferred tax assets
$21,380,674$22,290,813Liabilities and Shareholders' EquityCurrent liabilities:Accounts payable
$724,802$593,585Current portion – deferred rent
35,00035,000Income tax payable
419,533316,995Total current liabilities
2,551,9602,539,619Deferred rent – less current portion
32,93242,043Accrued pension liability
3,076,4543,056,058Total shareholders' equity
18,304,22019,234,755Total liabilities and shareholders' equity
UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)Three Months EndedJune 3020122011Cash flows from operating activities:Net loss
$ (1,019,355)$ (1,331,307)Adjustments to reconcile net loss to net cash used in operations:Depreciation and amortization
288,548274,102Loss on disposal of equipment
5995,996Amortization of premium on marketable securities
8,09111,656Share-based consulting expense
1,6231,449Share-based compensation expense
162,435130,352Deferred income taxes
(9,111)(8,807)Changes in operating assets and liabilities:Accounts receivable, net
(122,672)(35,090)Other current assets
(106,432)(329,364)Accrued pension liability, net
41,02942,082Net cash used in operating activities
(701,701)(1,363,530)Cash flows from investing activities:Proceeds from maturity of held-to-maturity marketable securities
3,320,0001,500,000Proceeds from maturity of available-for-sale marketable securities
-2,750,059Purchases of held-to-maturity marketable securities
-(3,840,016)Purchases of available-for-sale marketable securities
(3,218,286)-Purchases of property, plant and equipment
(73,902)(70,865)Purchase of intangible assets
(4,440)(10,405)Net cash provided by investing activities
23,372328,773Cash flows from financing activities:Net proceeds from exercise of options
-126,550Net cash provided by financing activities
-126,550Effect of exchange rate changes on cash and cash equivalents
(18,642)5,575Net decrease in cash and cash equivalents
(696,971)(902,632)Cash and cash equivalents at beginning of year
4,653,2266,063,573Cash and cash equivalents at end of year
$3,956,255$5,160,941Supplemental disclosure of cash flow information: Cash paid during the period for income tax
Non-GAAP Financial Measures: The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization expenses from gross profit, operating expenses and operating loss. The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP. We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies. Therefore, our non-GAAP financial measures may not be comparable to those used by other companies. We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.
We use these non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes and incentive compensation for senior management because we believe such measures are one important indicator of the strength and the operating performance of our business. Analysts and investors frequently ask us for this information. We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.
Our non-GAAP operating loss during the three months ended June 30, 2012 and 2011 was approximately $561,000 and $934,000, respectively. The decrease in non-GAAP operating loss for the three months ended June 30, 2012 over the corresponding period a year ago is attributed to the increase in sales and gross profit percent, which more than offset the increase in spending, primarily in selling and marketing.Expense AdjustmentsGAAPShare-based
IntangiblesNon-GAAPThree-Months Ended June 30, 2012 Gross Profit
$9,000$4,837,000% of net sales
86.5%86.7%Operating ExpensesGeneral and administrative
(47,000)959,000Research and development
(1,000)550,000Selling and marketing
($561,000)Three Months Ended June 30, 2011Gross Profit
$8,000$3,957,000% of net sales
84.8%85.0%Operating ExpensesGeneral and administrative
(40,000)908,000Research and development
(3,000)445,000Selling and marketing
|SOURCE Uroplasty, Inc.|
Copyright©2012 PR Newswire.
All rights reserved